Fast Track to MS Drug  

Oleh:

Sheridan, Cormac

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Nature Biotechnology: The Science and Business of Biotechnology vol. 22 no. 8 (Agu. 2004), page 939-942.
Topik: DRUG; MS drug

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: NN9.1 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Will the new multiple sclerosis drug antegren be the next blockbuster drug as some analysts predict? Cormac Sheridan investigates. The eagerly anticipated launch of the humanized monoclonal antibody antegren (natalizumab), developed by biogen idec of cambridge, massachusetts and elan of dublin as a treatment for multiple sclerosis (MS), is poised to shake up a market currently dominated by a handful of products. It could also be the harbinger of a new era of MS therapy that would be characterized by far greater heterogeneity and specificity of treatment options.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali